MENU

Click here to

×

Are you sure ?

Yes, do it No, cancel

Use of Small 3D Radiochromic Dosimeters and a Motion Phantom for Dose Verification of Dynamic MLC Tracking Radiotherapy

F Costa1*, M Menten1 , S Doran2 , J Adamovics3 , I Hanson1 , S Nill1 , U Oelfke1 , (1) The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, (2) CRUK Cancer Imaging Centre, The Institute of Cancer Research, London, (3) Rider University, Lawrenceville, NJ

Presentations

(Sunday, 7/29/2018) 2:05 PM - 3:00 PM

Room: Room 209

Purpose: To investigate the use of small size PRESAGE® 3D dosimeters in combination with a lung motion phantom for dosimetric verification of real-time MLC-tracked radiotherapy treatments.

Methods: A cylindrical insert holding a PRESAGE® sample of 3.5cm diameter and 5cm length was placed in the QUASAR™ MRI4D motion phantom, simulating a tumour in the lungs. A CT scan of this set up was acquired and transferred to the research Monaco treatment planning system. A plan with four equidistant spaced beams and a field size of 1x2.5cm² was created and calculated with Monte Carlo algorithm with a maximum dose of 9.7Gy. Three samples of PRESAGE® were irradiated in three different scenarios: (1) static: static phantom, non-tracking; (2) motion: moving phantom, non-tracking (3) tracking: moving phantom, with tracking. The in-house MLC-tracking software DynaTrack was used to interface with our research Elekta Synergy Linac and dynamically move the MLC based on the target position reported by the motion phantom. Log-files containing the recorded MLC and phantom positions every 40ms allowed to reconstruct the dose delivered to the samples under motion and tracking. PRESAGE® samples were imaged with an in-house telecentric optical-CT scanner and reconstructed with 0.2mm resolution.

Results: Dosimetric changes between samples under motion and tracking are visible. Comparison between simulated and measured 3D dose showed good agreement for all three irradiation scenarios (static: 99.2%; motion: 99.7%; tracking: 99.3% with a 3%, 2mm and a 10% threshold local gamma criterion), failing only at the edges of the PRESAGE® samples (~6mm) for doses ≥30% of maximum dose.

Conclusion: We showed that small PRESAGE® samples can be used to validate the delivery of dynamic MLC-tracked radiotherapy. Despite the discrepancies found at the edges of the samples, due to sample non-uniform properties, the methodology used was reproducible, easy to set up and provides valuable 3D dosimetric information.

Funding Support, Disclosures, and Conflict of Interest: The authors acknowledge Elekta AB, Stockholm, Sweden; NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR. The ICR is supported by Cancer Research UK under Programme C33589/A19727.

Keywords

Quality Assurance, Treatment Verification, Dosimetry

Taxonomy

TH- External beam- photons: Quality Assurance - IMRT

Contact Email